CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan

FDA's proposed transfer of therapeutic biologic reviews to the drug center could negatively affect the newly created CBER Office of Cellular, Tissue & Gene Therapies, Acting Director Phillip Noguchi, MD, said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet